Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?
Oseltamivir, an antiviral medication that has been used for influenza prophylaxis and treatment since 1999 and now available as a generic drug, is being considered for over-the-counter (OTC) status to allow individuals to access treatment without a prescription. This proposal has engendered controversy. With the rising availability of at-home diagnostic tests and the ever-present threat of an influenza pandemic, it is timely to revisit issues surrounding this controversy. In this commentary, we examine the potential benefits and risks of reclassifying oseltamivir as an OTC drug to enhance access to rapid influenza treatment. Additionally, we explore alternative models to improve oseltamivir accessibility, potentially utilizing rapid influenza testing. As newer drugs to treat influenza are proven safe and effective, they would be subject to similar considerations.
Authors
- Kyueun Lee (ORCID: https://orcid.org/0000-0002-0013-4733)
- Janet A. Englund (ORCID: https://orcid.org/0000-0003-1134-4178)
- Andrew T. Pavia (ORCID: https://orcid.org/0000-0002-3066-580X)
Institutions
- University of Washington (US)
- University of Utah (US)
- Spencer Foundation (US)
- Institute of Translational Health Sciences (US)
- Seattle Children's Hospital (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/infdis/jiaf152
- Citations
- 3
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06